JP7886328B2 - 抗cd25抗体 - Google Patents

抗cd25抗体

Info

Publication number
JP7886328B2
JP7886328B2 JP2023530329A JP2023530329A JP7886328B2 JP 7886328 B2 JP7886328 B2 JP 7886328B2 JP 2023530329 A JP2023530329 A JP 2023530329A JP 2023530329 A JP2023530329 A JP 2023530329A JP 7886328 B2 JP7886328 B2 JP 7886328B2
Authority
JP
Japan
Prior art keywords
sequence
antibody
antigen
cdr1
cdr2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023530329A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023550446A5 (cg-RX-API-DMAC7.html
JP2023550446A (ja
Inventor
オリーブ,ダニエル
ベンスーサン,アルマンド
ジュスティニアーニ,ジェローム
マリー-カルディネ,アン
フォウスサット,アルノー
ウアシーヌ,ジェミラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Université Paris Cité
Original Assignee
Université Paris Cité
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Université Paris Cité filed Critical Université Paris Cité
Publication of JP2023550446A publication Critical patent/JP2023550446A/ja
Publication of JP2023550446A5 publication Critical patent/JP2023550446A5/ja
Application granted granted Critical
Publication of JP7886328B2 publication Critical patent/JP7886328B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023530329A 2020-11-20 2021-11-19 抗cd25抗体 Active JP7886328B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20306424.1 2020-11-20
EP20306424 2020-11-20
PCT/EP2021/082383 WO2022106665A1 (en) 2020-11-20 2021-11-19 Anti-cd25 antibodies

Publications (3)

Publication Number Publication Date
JP2023550446A JP2023550446A (ja) 2023-12-01
JP2023550446A5 JP2023550446A5 (cg-RX-API-DMAC7.html) 2024-11-25
JP7886328B2 true JP7886328B2 (ja) 2026-07-07

Family

ID=73698744

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023530329A Active JP7886328B2 (ja) 2020-11-20 2021-11-19 抗cd25抗体

Country Status (9)

Country Link
US (1) US20240002522A1 (cg-RX-API-DMAC7.html)
EP (1) EP4247497A1 (cg-RX-API-DMAC7.html)
JP (1) JP7886328B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230118108A (cg-RX-API-DMAC7.html)
CN (1) CN116917318A (cg-RX-API-DMAC7.html)
AR (1) AR124123A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021380966A1 (cg-RX-API-DMAC7.html)
CA (1) CA3199006A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022106665A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023222886A1 (en) 2022-05-20 2023-11-23 Depth Charge Ltd Antibody-cytokine fusion proteins

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019175222A1 (en) 2018-03-13 2019-09-19 Tusk Therapeutics Ltd Anti-cd25 for tumour specific cell depletion
JP2020514363A (ja) 2017-03-17 2020-05-21 タスク セラピューティクス リミテッド 腫瘍特異的細胞枯渇のためのFc最適化抗CD25
JP2020525517A (ja) 2017-07-06 2020-08-27 タスク セラピューティクス リミテッド 腫瘍特異的細胞枯渇のための化合物及び方法
WO2020234399A1 (en) 2019-05-20 2020-11-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel anti-cd25 antibodies

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US61816A (en) 1867-02-05 bunbab and a
US96973A (en) 1869-11-16 saxton
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US7029872B2 (en) 2000-06-28 2006-04-18 Glycofi, Inc Methods for producing modified glycoproteins
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
KR101703299B1 (ko) 2007-06-01 2017-02-06 오픈 모노클로날 테크놀로지, 인코포레이티드 내생적 면역글로불린 유전자를 억제하고 트랜스제닉 인간 이디오타입 항체를 생산하기 위한 방법 및 조성물
WO2013165972A2 (en) * 2012-04-30 2013-11-07 Cell Signaling Technology, Inc. Anti-hepatitis b virus antibodies and use thereof
BR112021008486A2 (pt) * 2018-11-01 2021-10-26 Shandong New Time Pharmaceutical Co., Ltd Anticorpo biespecífico e seu uso

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020514363A (ja) 2017-03-17 2020-05-21 タスク セラピューティクス リミテッド 腫瘍特異的細胞枯渇のためのFc最適化抗CD25
JP2020525517A (ja) 2017-07-06 2020-08-27 タスク セラピューティクス リミテッド 腫瘍特異的細胞枯渇のための化合物及び方法
WO2019175222A1 (en) 2018-03-13 2019-09-19 Tusk Therapeutics Ltd Anti-cd25 for tumour specific cell depletion
WO2020234399A1 (en) 2019-05-20 2020-11-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel anti-cd25 antibodies

Also Published As

Publication number Publication date
JP2023550446A (ja) 2023-12-01
EP4247497A1 (en) 2023-09-27
AR124123A1 (es) 2023-02-15
CN116917318A (zh) 2023-10-20
US20240002522A1 (en) 2024-01-04
KR20230118108A (ko) 2023-08-10
AU2021380966A1 (en) 2023-06-22
CA3199006A1 (en) 2022-05-27
WO2022106665A1 (en) 2022-05-27

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230718

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241115

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260325

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260423

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260602

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260625

R150 Certificate of patent or registration of utility model

Ref document number: 7886328

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150